A glaucoma drainage device includes an elongated body extending axially from a distal end to a proximal end. The distal end forms a wedge with a leading distal edge. During implantation of the device into the suprachoroidal space of the eye, the wedge can facilitate penetration into and spreading open the tissue of the suprachoroidal space. The elongate body has one or more outer surfaces that define at least one open groove extending from at or near the proximal end towards the distal end of the body. With the distal end of the elongate body located in the suprachoroidal space of the eye and the distal end of the elongate body extending into the anterior chamber of the eye, the at least one open groove is configured such that aqueous humor flows along the open groove from the anterior chamber of the eye to the suprachoroidal space of the eye.

In some embodiments, a microsurgical instrument includes a trocar having a rigid, hollow shaft formed with a lumen extending from a proximal end to a distal end of the shaft. The distal end of the shaft may be shaped for tissue penetration. The instrument may further include a composite microcannula slidably engaged with the trocar in the lumen. The microcannula includes a light guide and a flexible hollow tube having an outer diameter less than an inner diameter of the lumen in the trocar. Other embodiments include placing the microcannula in the lumen of the trocar, illuminating the end of the trocar by illuminating the end of the microcannula, advancing the trocar from a selected entry point on an eye into a selected structure in the eye, and extending the illuminated end of the microcannula from the trocar into the selected structure.

Methods and systems for applying beta radiation to a treatment area, such as a target area of a bleb, in combination with combined glaucoma and cataract surgery. The methods and systems herein may help achieve and/or maintain a healthy intraocular pressure, maintain functioning blebs and/or drainage holes arising from glaucoma drainage procedures or surgeries, help avoid scar formation or wound reversion, inhibit or reduce fibrogenesis and/or inflammation in the blebs or surrounding areas, etc.

An aqueous humor outflow device includes an arcuate scaffold that fits within a conventional aqueous humor outflow pathway of a mammalian eye to receive aqueous humor from a trabecular meshwork of the mammalian eye and allow flow of the aqueous humor through the arcuate scaffold to one or more collector channels that originate in a posterior wall of a Schlemm's canal. The arcuate scaffold includes a first arcuate rail, and a second arcuate rail spaced apart from, and substantially parallel to, the first arcuate rail. The first and second arcuate rails each have an anterior edge that is adjacent to the trabecular meshwork when inserted in the Schlemm's canal, and a posterior edge that is adjacent to the posterior wall of the Schlemm's canal. Structural components coupled to the first arcuate rail and the second arcuate rail maintain the respective anterior and posterior edges of the first and second arcuate rails spaced apart from, and substantially parallel to, each other.

Systems, devices, and methods for treating a glaucomatous eye are provided. Embodiments may provide a treatment probe for treating an eye of a patient. The treatment probe may have an elongate body with a contact surface at a distal end of the elongate body. A treatment fiber or light source may be housed in the treatment probe and may be configured to direct treatment energy from the contact surface. The contact surface may be configured to couple to a surface of the eye to deliver the energy into the target area. In many embodiments the contact surface may have a convex configuration with a rounded outer shape and edge that facilitates the sweeping of the probe surface across the eye during treatment delivery. In some embodiments the probe may be swept in arc motions while delivering treatment energy to the eye.

Implanting an intraocular shunt into an eye can involve creating an opening in the cornea and positioning a shunt in the anterior chamber of the eye such that the shunt terminates between layers of Tenon's capsule, thereby facilitating fluid flow out of the anterior chamber into a space between the layers of Tenon's capsule.

A method for manufacturing an inner drainage biomimetic stent for glaucoma. The inner drainage biomimetic stent for glaucoma comprises: a cylinder tube body with a hollow structure, and a plurality of straight tubes, provided inside the hollow structure of the tube body, for supporting a tube wall of the tube body. Proper placement of the inner drainage biomimetic stent for glaucoma can direct an aqueous humour to smoothly flow through an orifice expanded by the biomimetic stent, into Schlemm's canal. A collapsed Schlemm's canal is re-expanded by the flow of the aqueous humour to direct the aqueous humour to a collector canal, thereby lowering an intraocular pressure and achieving the goal of glaucoma treatment

Described here are systems and methods for accessing Schlemm’s canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm’s canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

Methods, systems, and compositions for maintaining functioning drainage blebs to reduce intraocular pressure (IOP) of an eye being treated for glaucoma. The methods, systems, and compositions feature the combination of a minimally invasive glaucoma surgery (MIGS) implant or procedure and the application of beta radiation to the bleb. The beta radiation can function to inhibit or reduce the inflammation and/or fibrogenesis that typically occurs after insertion of a MIGS implant and leads to bleb failure. By reducing inflammation and/or fibrogenesis, the MIGS implant and the blebs can remain functioning appropriately.

The present technology is directed to adjustable shunts for treating glaucoma. In particular, some embodiments provide shunts having a plurality of individually actuatable flow control elements that can control the flow of fluid through associated ports and/or flow lumens. For example, each individually actuatable flow control element can be actuated to block and/or unblock a corresponding port and/or flow lumen. Accordingly, the shunts described herein can be manipulated into a variety of configurations that provide different drainage rates based on whether the ports and/or flow lumens are blocked or unblocked, therefore providing a titratable glaucoma therapy for draining aqueous from the anterior chamber of the eye.